Selected article for: "coronavirus disease and excess mortality"
Author: Tzoulis, Ploutarchos; Grossman, Ashley B; Baldeweg, Stephanie E; Bouloux, Pierre; Kaltsas, Gregory
Title: MANAGEMENT OF ENDOCRINE DISEASE: Dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management
  • Cord-id: 80mgxmke
  • Document date: 2021_8_6
    • ID: 80mgxmke
    Snippet: This review examines the prevalence, aetiology, pathophysiology, prognostic value, and investigation of dysnatraemia in hospitalised COVID-19 patients, taking into account all relevant studies published in PubMed and Cochrane Library studies until March 2021. Hyponatraemia is commonly observed in patients with bacterial pneumonia and is an independent predictor for excess mortality and morbidity. However, it remains unknown whether this association applies to coronavirus disease-2019 (COVID-19).
    Document: This review examines the prevalence, aetiology, pathophysiology, prognostic value, and investigation of dysnatraemia in hospitalised COVID-19 patients, taking into account all relevant studies published in PubMed and Cochrane Library studies until March 2021. Hyponatraemia is commonly observed in patients with bacterial pneumonia and is an independent predictor for excess mortality and morbidity. However, it remains unknown whether this association applies to coronavirus disease-2019 (COVID-19). Several studies reported a 20–35% prevalence for hyponatraemia and 2–5% for hypernatraemia in patients admitted with COVID-19. In addition, hyponatraemia on admission was a risk factor for progression to severe disease, being associated with an increased likelihood for the need for invasive mechanical ventilation, with an odds ratio (OR) of 1.83–3.30. Hyponatraemia seems to be an independent risk factor for mortality, with an OR of 1.40–1.50 compared to normonatraemia, while hypernatraemia is related to even worse outcomes than hyponatraemia. Furthermore, preliminary data show an inverse association between serum sodium and interleukin-6 levels, suggesting that hyponatraemia might be used as a surrogate marker for the risk of a cytokine storm and the need for treatment with interleukin antagonists. In conclusion, dysnatraemia is common and carries a poor prognosis in COVID-19 patients, indicating that it may play a future role in risk stratification and individualising therapy.

    Search related documents:
    Co phrase search for related documents
    • abnormal level and acute ards respiratory distress syndrome: 1, 2
    • abnormal level and acute cardiac injury: 1, 2
    • abnormal level and acute kidney injury: 1
    • abnormal level and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abnormal level and admission rate: 1
    • abnormal level and adrenal insufficiency: 1
    • acute aki kidney injury and admission rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute aki kidney injury and longitudinal study: 1, 2, 3
    • acute ards respiratory distress syndrome and admission prevalent: 1
    • acute ards respiratory distress syndrome and admission rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute ards respiratory distress syndrome and adrenal crisis: 1
    • acute ards respiratory distress syndrome and adrenal insufficiency: 1, 2, 3
    • acute ards respiratory distress syndrome and longitudinal study: 1, 2, 3, 4, 5
    • acute cardiac injury and admission rate: 1, 2, 3
    • acute kidney injury and admission rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and longitudinal study: 1, 2, 3, 4, 5, 6
    • acute kidney injury common and admission rate: 1, 2, 3
    • acute respiratory syndrome and adrenal insufficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25